US20080280840A1 - Meloxicam for the treatment of respiratory diseases in pigs - Google Patents
Meloxicam for the treatment of respiratory diseases in pigs Download PDFInfo
- Publication number
- US20080280840A1 US20080280840A1 US12/114,509 US11450908A US2008280840A1 US 20080280840 A1 US20080280840 A1 US 20080280840A1 US 11450908 A US11450908 A US 11450908A US 2008280840 A1 US2008280840 A1 US 2008280840A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical composition
- meloxicam
- disease
- respiratory
- pigs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N CC1=CN=C(NC(=O)C2=C(O)C3=CC=CC=C3S(=O)(=O)N2C)S1 Chemical compound CC1=CN=C(NC(=O)C2=C(O)C3=CC=CC=C3S(=O)(=O)N2C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in pigs.
- Respiratory disease in pigs belongs to the most important health problems in swine production. Porcine respiratory disease is primarily caused by infectious agents, but environmental factors have a strong influence.
- the relevant pathogens include mycoplasmas, bacteria, and viruses (e.g., G. Christensen, V. Sorensen, and J. Mousing, Diseases of the Respiratory System, In: Diseases of Swine , B. E. Straw, S. D'Allaire, W. L. Mengeling, & D. J. Taylor (eds), Iowa State University Press, Ames, Iowa (1999) pp. 913-940).
- porcine respiratory disease The most important measures for the control of porcine respiratory disease are to improve herd management and housing conditions and introduce a vaccination program. However, if pigs have developed respiratory disease, they have to be treated.
- cyclooxygenase-2 plays a relevant role in the pathophysiology of porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae .
- Isolated porcine alveolar macrophages increase their COX-2 activity after exposure to Actinobacillus pleuropneumoniae (W. S. Cho & C. Chae, In vitro Effects of Actinobacillus pleuropneumoniae on Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Porcine Alveolar Macrophages, Am J Vet Res 64, (2003) pp. 1514-1518).
- in situ hybridization W. S. Cho & C.
- acetylsalicylic acid can be used for the treatment of pigs with respiratory disease.
- aspirin acetylsalicylic acid
- Ketoprofen and, to a lesser extent, flunixin decrease fever induced by experimental infection with Actinobacillus pleuropneumoniae (J. M. Swinkels, A. Pijpers, J. C. Vernooy, A. Van Nes, & J. H.
- Ketoprofen was further tested in a controlled, blinded clinical field study (M. F. De Jong, O, Sampimon, J. P. Arnaud, G. Theunissen, G. Groenland, & P. J. Werf, A Clinical Study with a Non Steroid Antiinflammatory Drug, 14, (1996) 659 IPVS). In this study, ketoprofen had no effect on clinical score, relapse, or cure rate.
- Meloxicam is a non-steroidal anti-inflammatory compound that belongs to the oxicam class and exerts potent anti-inflammatory, anti-exudative, and anti-pyretic activity.
- the efficacy of meloxicam as an adjunctive therapy in the treatment of respiratory infections in cattle has been widely proven.
- Recently meloxicam was approved for the treatment of MMA (A. Hirsch et al., J Vet Pharmacol Therap 26 (2003) pp. 355-360) and locomotor disorders in pigs (G. Friton et al., Berl Münch Tiermaschinemaschineschztl Wschr 116 (2003) pp. 421-426).
- the problem underlying the present invention was to provide a medication for the prevention or treatment of respiratory diseases in pigs, one of the most important health problems in swine production.
- meloxicam can be used for the treatment or prevention of respiratory diseases in pigs.
- the invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in pigs.
- the invention relates to a method of treating or preventing respiratory diseases in pigs, which method comprises administering an effective amount of meloxicam to the pigs in need thereof.
- the invention relates to veterinary preparation containing meloxicam as well as at least one antibiotic selected from the group consisting of ⁇ -lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides.
- Another aspect of the invention is a ready-to-use two-component system for the treatment of respiratory diseases in pigs, wherein:
- Still another aspect of the invention is an article of manufacture comprising packaging material contained within which is a composition consisting of meloxicam and a pharmaceutically acceptable carrier, and a label which indicates that the composition can be used to treat or prevent respiratory diseases in pigs.
- FIG. 1 shows the incidence of fever (rectal temperature ⁇ 40.56° C.) in percent following the first treatment in a group of pigs treated with oxytetracycline and meloxicam ( ⁇ ), in a group of pigs treated with oxytetracycline alone ( ⁇ ), and in the untreated control ( ⁇ ).
- FIG. 2 shows the efficacy of meloxicam in drinking water in reducing lung lesions caused by experimental Swine Influenza Virus (SIV) infection on study days 7 and 14.
- SIV Swine Influenza Virus
- the invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition in a form suitable for systemic or oral administration for the treatment or prevention of respiratory diseases in pigs.
- Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide) of formula
- NSAIDs non-steroidal-anti-inflammatory drugs
- Meloxicam and the sodium and meglumine salt thereof are described in EP-A-0 002 482 (corresponding to U.S. Pat. No. 4,233,299), each of which is hereby incorporated by reference.
- Meloxicam may be used according to the invention in the form of a physiologically acceptable acid addition salt.
- physiologically acceptable acid addition salts are meant, according to the invention, the meglumine, sodium, potassium, or ammonium salt, preferably the meloxicam meglumine salt.
- the pharmaceutical composition is administered corresponding to a daily dose of meloxicam ranging from 0.01 mg/kg to 5.0 mg/kg, preferably from 0.1 mg/kg to 3.5 mg/kg, in particular from 0.2 mg/kg to 2.0 mg/kg.
- the pharmaceutical composition is preferably administered in a form suitable for injection, in particular for intramuscular injection, or in form of water soluble granules for administration via drinking water or as top dressing on feed.
- a suitable injection formulation is disclosed, for example, in Example 25 of EP-A-0 002 482.
- injection solutions may additionally contain excipients selected from among citric acid, lecithin, gluconic acid, tartaric acid, phosphoric acid and EDTA or the salts thereof as disclosed in the Examples 1 to 5 of the International Patent Application WO 01/97813 (corresponding to U.S. Patent App. Pub No. 2002/0035107), each of which is hereby incorporated by reference.
- an injection solution of meloxicam for needleless injections is disclosed in the International Patent Application WO 03/049733 (corresponding to U.S. Patent App. Pub No. 2003/0119825), each of which is hereby incorporated by reference.
- Suitable water soluble granules for administration via drinking water or as top dressing on feed are, for example, disclosed in the International Patent Application PCT/EP03/11802 (corresponding to U.S. Patent App. Pub No. 2004/0234596), each of which is hereby incorporated by reference.
- the meloxicam granules contain a binder which may be selected from among hydroxypropylmethylcellulose, polyvinylpyrrolidone, gelatine, starch, and polyethylene glycol ether, preferably hydroxypropylmethylcellulose, polyvinylpyrrolidone, and polyethylene glycol ether, and most preferably hydroxypropylmethylcellulose and polyvinylpyrrolidone.
- a binder which may be selected from among hydroxypropylmethylcellulose, polyvinylpyrrolidone, gelatine, starch, and polyethylene glycol ether, preferably hydroxypropylmethylcellulose, polyvinylpyrrolidone, and polyethylene glycol ether, and most preferably hydroxypropylmethylcellulose and polyvinylpyrrolidone.
- meloxicam granules contain a sweetener, which may be selected from among sodium saccharine, aspartame, and SUNETT® (acesulfame K), preferably sodium saccharine or aspartame.
- a sweetener which may be selected from among sodium saccharine, aspartame, and SUNETT® (acesulfame K), preferably sodium saccharine or aspartame.
- meloxicam granules containing a flavoring agent which may be selected from among vanilla, honey flavoring, apple flavoring, and contramarum, preferably honey flavoring and apple flavoring.
- meloxicam granules in which the carrier is selected from among lactose, glucose, mannitol, xylitol, sucrose, and sorbitol, preferably glucose, lactose, or sorbitol, more preferably glucose or lactose, and most preferably glucose.
- the carrier is selected from among lactose, glucose, mannitol, xylitol, sucrose, and sorbitol, preferably glucose, lactose, or sorbitol, more preferably glucose or lactose, and most preferably glucose.
- meloxicam granules in which the content of meloxicam is between 0.05% and 4%, preferably between 0.1% and 2%, preferably between 0.3% and 1.8%, more preferably between 0.4% and 1.5%, and most preferably 1.2%. Also particularly preferred are meloxicam granules which contain meglumine and meloxicam in a molar ratio of about 9:8 to 12:8, preferably 10:8.
- Meloxicam can be used according to the invention to treat or prevent respiratory diseases in any breed of swines.
- pigs selected from the swine breeds American Landrace, American Yorkshire, Angeln Saddleback, Arapawa Island, Ba Xuyen, Bantu, Bazna, Beijing Black, else Black Pied, Belgian Landrace, Bentheim Black Pied, Berkshire, Black Slavonian, British Landrace, British Lop, Bulgarian White, Cantonese, Chester White, Czech Improved White, Danish Landrace, Dermantsi Pied, Duroc, Dutch Landrace, Fengjing, Finnish Landrace, French Landrace, German Landrace, Gloucestershire Old Spots, Guinea Hog, Hampshire, Hereford, Hezuo, Iberian, Italian Landrace, Jinhua, Kele, Krskopolje, Kunekune, Lacombe, Large Black, Large Black-white, Large White, Lithuanian Native, Mangalitsa, Meishan, Middle White, Minzhu, Mong Cai, Mukota
- meloxicam is in conjunction with an antibiotic, preferably selected from the group consisting of ⁇ -lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides. Most preferred are amoxicillin, oxytetracycline, florfenicol, tylosin, tilmicosin, and sulfamethazine.
- the dose of antibiotic is not critical per se and depends strongly on the different efficacies of the antibiotics used. As a rule up to 150.0 mg/kg, preferably from 0.1 mg/kg to 120 mg/kg, in particular from 10 mg/kg to 110 mg/kg of an antibiotic are co-administered together with meloxicam.
- Amoxicillin 5 mg/kg to 30 mg/kg, in particular about 10 mg/kg
- Oxytetracycline 20 mg/kg to 70 mg/kg, in particular about 30 mg/kg
- Florfenicol 10 mg/kg to 20 mg/kg, in particular about 15 mg/kg
- Tylosin 10 mg/kg to 25 mg/kg, in particular about 16 mg/kg
- Tilmicosin 5 mg/kg to 30 mg/kg, in particular 10 mg/kg to 20 mg/kg
- Sulfamethazine 80 mg/kg to 150 mg/kg, in particular about 100 mg/kg.
- co-administration in defining use of meloxicam and an antibiotic, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects, in particular, reduction of the symptoms of the respiratory disease in the affected pig of the drug combination.
- the phrase also is intended to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single capsule or injection solution having a fixed ratio of these active agents or in multiple, separate capsules for each agent.
- meloxicam and the antibiotic may be co-administered in a combined form, or separately or separately and sequentially wherein the sequential administration is preferably close in time.
- the medicament according to this invention is used for the prevention or treatment of Porcine Respiratory Disease Complex in growing or fattening pigs; or for the prevention or treatment of respiratory diseases in pigs caused by mycoplasmas, in particular Mycoplasma hyopneumoniae, Mycoplasma hyorhinis , for the prevention or treatment of respiratory diseases in pigs caused by bacteria in particular Actinobacillus spp., in particular Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Arcanobacterium pyogenes, Streptococcus spp., and Staphylococcus spp., or for the prevention or treatment of respiratory diseases in pigs caused by viruses, in particular Swine Influenza Virus, Aujetzky's Virus, Porcine Reproductive and Respiratory Syndrome Virus, Porcine Circovirus, and Transmissible Gastroenteritis and Porcine Respiratory Coronavirus.
- the medicament according to this invention is used for the prevention or treatment of respiratory diseases in pigs caused by Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Streptococcus suis , Swine Influenza Virus, and Porcine Reproductive and Respiratory Syndrome Virus.
- the study was a controlled, randomized, and blinded exploratory study under experimental conditions with a parallel group design.
- Crossbred pigs of about 10 weeks of age were challenged with a single intranasal inoculation of Actinobacillus pleuropneumoniae . The next day, pigs were included in the study and treated if they fulfilled the following inclusion criteria: rectal temperature ⁇ 40° C. and clinical symptoms of acute or subacute infectious respiratory disease.
- Meloxicam was administered as 0.5% solution, at 0.5 mg/kg daily on three consecutive days, oxytetracycline as 20% long-acting solution (OXYTET® 200) at 20 mg/kg as single injection.
- the aim of this study was to test the efficacy of meloxicam granules dissolved in drinking water in pigs experimentally infected with Swine Influenza Virus (SIV).
- the study was an open, negative controlled randomized laboratory study carried out according to GCP at one site.
- the study animals were clinically examined daily on study days 0 to 7 and 14. They were weighed on study days 7 and 14. All animals of group A and 5 animals of group C were euthanized and necropsied on study day 7; the remaining study animals, group B and 5 study animals of group C, on study day 14.
- FIG. 2 shows the quantity of lung lesions by lung lobe on study days 7 and 14.
- meloxicam-treated pigs reached significantly higher weight gains during the two weeks following infection than untreated controls.
- Mean daily weight gain in the interval study day 0 to 7 was 557 g in meloxicam group A and 257 g in the control (5 study animals of group C).
- mean daily weight gain was 629 g in meloxicam group B and 486 g in the control (5 study animals of group C).
- Growth performance data for each group included the Average Daily Gain (ADG) for the following trial periods: d90 to d117, d117 to d170 (slaughtering), and d90 to d170 of age. Mortality was also calculated for these time periods. Slaughterhouse records per group, included the percentage of each lung surface (LS) affected by chronic and acute respiratory lesions.
- ADG Average Daily Gain
- RS and AIM in the meloxicam group were significantly lower (p ⁇ 0.05) compared to the control group. Same applies for LS affected by acute lesions (p ⁇ 0.01), while no differences were observed for LS in chronic cases (Table 1).
Abstract
A method of treating or preventing a respiratory disease in a pig, the method comprising administering to the pig in need thereof an effective amount of meloxicam or a pharmaceutically acceptable salt thereof.
Description
- This application is a continuation of U.S. application Ser. No. 11/047,920, filed Feb. 1, 2005, which is hereby incorporated by reference, and further claims priority to European Application No. EP 04 004 054.5, filed Feb. 23, 2004, which is hereby incorporated by reference.
- 1. Technical Field
- The invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in pigs.
- 2. Background Information
- Respiratory disease in pigs belongs to the most important health problems in swine production. Porcine respiratory disease is primarily caused by infectious agents, but environmental factors have a strong influence. The relevant pathogens include mycoplasmas, bacteria, and viruses (e.g., G. Christensen, V. Sorensen, and J. Mousing, Diseases of the Respiratory System, In: Diseases of Swine, B. E. Straw, S. D'Allaire, W. L. Mengeling, & D. J. Taylor (eds), Iowa State University Press, Ames, Iowa (1999) pp. 913-940).
- The most important measures for the control of porcine respiratory disease are to improve herd management and housing conditions and introduce a vaccination program. However, if pigs have developed respiratory disease, they have to be treated.
- Current therapy of porcine respiratory disease includes treatment with antibiotics. The successful use of various types of antibiotics is described, including β-lactams, quinolones, and tetracyclines (e.g., 1. Lang, M. Rose, E. Thomas, & E. Zschiesche, A Field Study of Cefquinome for the Treatment of Pigs with Respiratory Disease, Revue Med Vet 8-9, (2002) pp. 575-580).
- It is known that cyclooxygenase-2 (COX-2) plays a relevant role in the pathophysiology of porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae. Isolated porcine alveolar macrophages increase their COX-2 activity after exposure to Actinobacillus pleuropneumoniae (W. S. Cho & C. Chae, In vitro Effects of Actinobacillus pleuropneumoniae on Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Porcine Alveolar Macrophages, Am J Vet Res 64, (2003) pp. 1514-1518). Moreover, in situ hybridization (W. S. Cho & C. Chae, Expression of Cyclooxygenase-2 in Swine Naturally Infected with Actinobacillus pleuropneumoniae. Vet Pathol 40, (2003) pp. 25-31) and immunohistochemistry (W. S. Cho & C. Chae, Immunohistochemical Detection of Cyclooxygenase-2 in Lungs of Pigs Naturally Infected with Actinobacillus pleuropneumoniae, J Comp Pathol 127, (2002) pp. 274-279) showed increased COX-2 expression in lungs of pigs naturally infected with Actinobacillus pleuropneumoniae.
- Moreover, it is well-known that acetylsalicylic acid (aspirin) can be used for the treatment of pigs with respiratory disease. However, little information on controlled clinical studies is available: for a review, see A. Laval, Utilisation des Anti-inflammatoires chez le Porc, Rec Méd Vét 168 (8/9) (1992) pp. 733-744. Ketoprofen, and, to a lesser extent, flunixin decrease fever induced by experimental infection with Actinobacillus pleuropneumoniae (J. M. Swinkels, A. Pijpers, J. C. Vernooy, A. Van Nes, & J. H. Verheijden, Effects of Ketoprofen and Flunixin in Pigs Experimentally Infected with Actinobacillus pleuropneumoniae, J Vet Pharmacol Ther 17, (1994) pp. 299-303). However, no effects on lung lesions were observed. Ketoprofen was further tested in a controlled, blinded clinical field study (M. F. De Jong, O, Sampimon, J. P. Arnaud, G. Theunissen, G. Groenland, & P. J. Werf, A Clinical Study with a Non Steroid Antiinflammatory Drug, 14, (1996) 659 IPVS). In this study, ketoprofen had no effect on clinical score, relapse, or cure rate.
- Indomethacin alleviated experimental endotoxin-induced respiratory failure in pigs (N. C. Olson, T. T. Brown, J. R. Anderson, & D. L. Anderson, Dexamethasone and Indomethacin Modify Endotoxin-Induced Respiratory Failure in Pigs, J Appl Physiol 58, (1985) pp. 274-284).
- Meloxicam is a non-steroidal anti-inflammatory compound that belongs to the oxicam class and exerts potent anti-inflammatory, anti-exudative, and anti-pyretic activity. The efficacy of meloxicam as an adjunctive therapy in the treatment of respiratory infections in cattle has been widely proven. Recently meloxicam was approved for the treatment of MMA (A. Hirsch et al., J Vet Pharmacol Therap 26 (2003) pp. 355-360) and locomotor disorders in pigs (G. Friton et al., Berl Münch Tierärztl Wschr 116 (2003) pp. 421-426).
- A review article (P. Lees, The Pharmacokinetics of Drugs Used in the Treatment of Respiratory Diseases in Cattle and Pigs, (1991) pp. 67-74, Hatfield, U.K. Proc. Royal Vet. Coll.) focuses on pharmacokinetics used in the treatment of respiratory disease in cattle and pigs; however, non-steroidal anti-inflammatory drugs data for pigs was almost entirely lacking and only lists data for cattle including meloxicam.
- The use of meloxicam in conjunction with antibiotics in bovine respiratory disease is well-established (H. Schmidt, H. Philipp, E. Salomon, & K. Okkinga, Effekte der zusätzlichen Gabe von Metacam (Meloxicam) auf den Krankheitsverlauf bei Rindern mit Atemwegserkrankungen, Der praktische Tierarzt 81 (2000) pp. 240-244) and registered in the EU. However, to date no information on the use of meloxicam in pigs with respiratory disease is publicly available.
- Since the pharmacokinetics in pigs and cattle differ substantially for meloxicam (plasma half-time in cattle is 26 hours whereas it is 2.5 hours in pigs), there is no expectation that the successful use of meloxicam in cattle should also be beneficial for pigs. Moreover, the causative agents for bovine and porcine respiratory disease differ substantially.
- The problem underlying the present invention was to provide a medication for the prevention or treatment of respiratory diseases in pigs, one of the most important health problems in swine production.
- It has been found surprisingly that meloxicam can be used for the treatment or prevention of respiratory diseases in pigs.
- Accordingly, the invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in pigs.
- Moreover, the invention relates to a method of treating or preventing respiratory diseases in pigs, which method comprises administering an effective amount of meloxicam to the pigs in need thereof.
- Furthermore, the invention relates to veterinary preparation containing meloxicam as well as at least one antibiotic selected from the group consisting of β-lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides.
- Another aspect of the invention is a ready-to-use two-component system for the treatment of respiratory diseases in pigs, wherein:
-
- (a) one component contains meloxicam and a pharmaceutically acceptable carrier; and
- (b) the other component contains at least one antibiotic selected from the group consisting of β-lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides and a pharmaceutically acceptable carrier.
- Still another aspect of the invention is an article of manufacture comprising packaging material contained within which is a composition consisting of meloxicam and a pharmaceutically acceptable carrier, and a label which indicates that the composition can be used to treat or prevent respiratory diseases in pigs.
-
FIG. 1 shows the incidence of fever (rectal temperature≧40.56° C.) in percent following the first treatment in a group of pigs treated with oxytetracycline and meloxicam (♦), in a group of pigs treated with oxytetracycline alone (◯), and in the untreated control (Δ). -
FIG. 2 shows the efficacy of meloxicam in drinking water in reducing lung lesions caused by experimental Swine Influenza Virus (SIV) infection onstudy days - Preferably the invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition in a form suitable for systemic or oral administration for the treatment or prevention of respiratory diseases in pigs. Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide) of formula
- is an active substance which belongs to the group of NSAIDs (non-steroidal-anti-inflammatory drugs). Meloxicam and the sodium and meglumine salt thereof (N-methyl-D-glucamine salt) are described in EP-A-0 002 482 (corresponding to U.S. Pat. No. 4,233,299), each of which is hereby incorporated by reference.
- Meloxicam may be used according to the invention in the form of a physiologically acceptable acid addition salt. By physiologically acceptable acid addition salts are meant, according to the invention, the meglumine, sodium, potassium, or ammonium salt, preferably the meloxicam meglumine salt.
- In a further preferred embodiment, the pharmaceutical composition is administered corresponding to a daily dose of meloxicam ranging from 0.01 mg/kg to 5.0 mg/kg, preferably from 0.1 mg/kg to 3.5 mg/kg, in particular from 0.2 mg/kg to 2.0 mg/kg.
- The pharmaceutical composition is preferably administered in a form suitable for injection, in particular for intramuscular injection, or in form of water soluble granules for administration via drinking water or as top dressing on feed.
- A suitable injection formulation is disclosed, for example, in Example 25 of EP-A-0 002 482. Furthermore, such injection solutions may additionally contain excipients selected from among citric acid, lecithin, gluconic acid, tartaric acid, phosphoric acid and EDTA or the salts thereof as disclosed in the Examples 1 to 5 of the International Patent Application WO 01/97813 (corresponding to U.S. Patent App. Pub No. 2002/0035107), each of which is hereby incorporated by reference. Moreover, an injection solution of meloxicam for needleless injections is disclosed in the International Patent Application WO 03/049733 (corresponding to U.S. Patent App. Pub No. 2003/0119825), each of which is hereby incorporated by reference.
- Suitable water soluble granules for administration via drinking water or as top dressing on feed are, for example, disclosed in the International Patent Application PCT/EP03/11802 (corresponding to U.S. Patent App. Pub No. 2004/0234596), each of which is hereby incorporated by reference.
- In a preferred embodiment of the invention, the meloxicam granules contain a binder which may be selected from among hydroxypropylmethylcellulose, polyvinylpyrrolidone, gelatine, starch, and polyethylene glycol ether, preferably hydroxypropylmethylcellulose, polyvinylpyrrolidone, and polyethylene glycol ether, and most preferably hydroxypropylmethylcellulose and polyvinylpyrrolidone.
- In another preferred embodiment of the invention, meloxicam granules contain a sweetener, which may be selected from among sodium saccharine, aspartame, and SUNETT® (acesulfame K), preferably sodium saccharine or aspartame.
- Particularly preferred according to the invention are meloxicam granules containing a flavoring agent which may be selected from among vanilla, honey flavoring, apple flavoring, and contramarum, preferably honey flavoring and apple flavoring.
- Also particularly preferred are meloxicam granules in which the carrier is selected from among lactose, glucose, mannitol, xylitol, sucrose, and sorbitol, preferably glucose, lactose, or sorbitol, more preferably glucose or lactose, and most preferably glucose.
- Most preferred are the following granules of meloxicam recipes:
-
-
g/100 g Meloxicam 0.6 Meglumine 0.42 Hydroxypropylmethylcellulose 3.00 Povidone 2.00 Glucose monohydrate 93.98 -
-
g/100 g Meloxicam 1.2 Meglumine 0.84 Hydroxypropylmethylcellulose 3.00 Collidone 25 2.0 Glucose Monohydrate 92.96 -
-
g/100 g Meloxicam 0.6 Meglumine 0.42 Pharmacoat 606 4.0 Macrogol 6000 1.0 Acesulfame K 0.3 Lactose 93.68 -
-
g/100 g Meloxicam 0.6 Meglumine 0.42 Pharmacoat 606 4.75 Macrogol 6000 0.25 Acesulfame K 0.3 Liquid vanilla flavoring 0.05 Lactose 93.63 - Particularly preferred are meloxicam granules in which the content of meloxicam is between 0.05% and 4%, preferably between 0.1% and 2%, preferably between 0.3% and 1.8%, more preferably between 0.4% and 1.5%, and most preferably 1.2%. Also particularly preferred are meloxicam granules which contain meglumine and meloxicam in a molar ratio of about 9:8 to 12:8, preferably 10:8.
- Meloxicam can be used according to the invention to treat or prevent respiratory diseases in any breed of swines. Preferably pigs selected from the swine breeds American Landrace, American Yorkshire, Angeln Saddleback, Arapawa Island, Ba Xuyen, Bantu, Bazna, Beijing Black, Belarus Black Pied, Belgian Landrace, Bentheim Black Pied, Berkshire, Black Slavonian, British Landrace, British Lop, Bulgarian White, Cantonese, Chester White, Czech Improved White, Danish Landrace, Dermantsi Pied, Duroc, Dutch Landrace, Fengjing, Finnish Landrace, French Landrace, German Landrace, Gloucestershire Old Spots, Guinea Hog, Hampshire, Hereford, Hezuo, Iberian, Italian Landrace, Jinhua, Kele, Krskopolje, Kunekune, Lacombe, Large Black, Large Black-white, Large White, Lithuanian Native, Mangalitsa, Meishan, Middle White, Minzhu, Mong Cai, Mukota, Mora Romagnola, Moura, Mulefoot, Neijiang, Ningxiang, Norwegian Landrace, Ossabaw Island, Oxford Sandy and Black, Philippine Native, Pietrain, Poland China, Red Wattle, Saddleback, Spots, Swabian-Hall, Swedish Landrace, Tamworth, Thuoc Nhieu, Tibetan, Turopolje, Vietnamese Potbelly, Welsh, and Wuzhishan, in particular American Landrace, Belgian Landrace, British Landrace, Danish Landrace, Dutch Landrace Finnish Landrace, French Landrace, German Landrace, Italian Landrace, and Pietrain can be treated with meloxicam according to the present invention.
- Furthermore preferred is the administration of meloxicam is in conjunction with an antibiotic, preferably selected from the group consisting of β-lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides. Most preferred are amoxicillin, oxytetracycline, florfenicol, tylosin, tilmicosin, and sulfamethazine.
- The dose of antibiotic is not critical per se and depends strongly on the different efficacies of the antibiotics used. As a rule up to 150.0 mg/kg, preferably from 0.1 mg/kg to 120 mg/kg, in particular from 10 mg/kg to 110 mg/kg of an antibiotic are co-administered together with meloxicam.
- The following dose ranges are most preferred:
-
Amoxicillin: 5 mg/kg to 30 mg/kg, in particular about 10 mg/kg; Oxytetracycline: 20 mg/kg to 70 mg/kg, in particular about 30 mg/kg; Florfenicol: 10 mg/kg to 20 mg/kg, in particular about 15 mg/kg; Tylosin: 10 mg/kg to 25 mg/kg, in particular about 16 mg/kg; Tilmicosin: 5 mg/kg to 30 mg/kg, in particular 10 mg/kg to 20 mg/kg; and Sulfamethazine: 80 mg/kg to 150 mg/kg, in particular about 100 mg/kg. - The phrase “co-administration” (or “administration in conjunction with”), in defining use of meloxicam and an antibiotic, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects, in particular, reduction of the symptoms of the respiratory disease in the affected pig of the drug combination. The phrase also is intended to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single capsule or injection solution having a fixed ratio of these active agents or in multiple, separate capsules for each agent.
- Accordingly, meloxicam and the antibiotic may be co-administered in a combined form, or separately or separately and sequentially wherein the sequential administration is preferably close in time.
- Preferably the medicament according to this invention is used for the prevention or treatment of Porcine Respiratory Disease Complex in growing or fattening pigs; or for the prevention or treatment of respiratory diseases in pigs caused by mycoplasmas, in particular Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, for the prevention or treatment of respiratory diseases in pigs caused by bacteria in particular Actinobacillus spp., in particular Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Arcanobacterium pyogenes, Streptococcus spp., and Staphylococcus spp., or for the prevention or treatment of respiratory diseases in pigs caused by viruses, in particular Swine Influenza Virus, Aujetzky's Virus, Porcine Reproductive and Respiratory Syndrome Virus, Porcine Circovirus, and Transmissible Gastroenteritis and Porcine Respiratory Coronavirus.
- Most preferably the medicament according to this invention is used for the prevention or treatment of respiratory diseases in pigs caused by Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Streptococcus suis, Swine Influenza Virus, and Porcine Reproductive and Respiratory Syndrome Virus.
- The Examples that follow serve to illustrate the use of meloxicam according to the invention. They are intended solely as possible procedures described by way of example, without restricting the invention to their content.
- The study was a controlled, randomized, and blinded exploratory study under experimental conditions with a parallel group design.
- Crossbred pigs of about 10 weeks of age were challenged with a single intranasal inoculation of Actinobacillus pleuropneumoniae. The next day, pigs were included in the study and treated if they fulfilled the following inclusion criteria: rectal temperature≧40° C. and clinical symptoms of acute or subacute infectious respiratory disease.
- Twenty-four (12 castrated male and 12 female) pigs were included and randomly allocated to three treatment groups with 8 pigs per group. The treatment groups were:
-
Group Treatment 1 untreated 2 oxytetracycline 3 oxytetracycline and meloxicam - Meloxicam was administered as 0.5% solution, at 0.5 mg/kg daily on three consecutive days, oxytetracycline as 20% long-acting solution (OXYTET® 200) at 20 mg/kg as single injection.
- Relevant criteria for the evaluation of efficacy were incidence of fever, clinical parameters of respiratory disease, deaths, and lung lesions at
necropsy 10 days after first treatment or after spontaneous death. The percentage of affected lung tissue was calculated by lobe and averaged for the total lung. - Challenge with Actinobacillus pleuropneumoniae lead to severe pleuropneumonia within 12 hours.
- The incidence of fever (rectal temperature≧40.56° C.) following the first treatment was lower in group 3 (♦) than in groups 1 (Δ), and 2 (◯) (cp.
FIG. 1 ). - The best treatment response in clinical parameters was observed in group 3.
- The number of pigs which died during the three days following first treatment is displayed below.
-
Group (n = 8 per group) Deaths 1 7 2 1 3 0 - The mean extent of lung lesions was less severe in group 3 than in the other groups (see below).
-
Group Lung lesions (%) 1 60 2 35 3 14 - Meloxicam in addition to antibiotic treatment effectively reduced fever, clinical symptoms of respiratory disease, deaths, and the extent of lung lesions in pigs with experimental Actinobacillus pleuropneumoniae-infection.
- The aim of this study was to test the efficacy of meloxicam granules dissolved in drinking water in pigs experimentally infected with Swine Influenza Virus (SIV).
- The study was an open, negative controlled randomized laboratory study carried out according to GCP at one site.
- Meloxicam granules containing 6 mg meloxicam per gram were offered to the pigs in the treatment groups (A+B) via drinking water in a concentration of 1 g granules per liter drinking water ad libitum for 7 consecutive days. This resulted in an actual meloxicam uptake of 0.8 mg per kg body weight per day. The pigs in the control group (C) received municipal drinking water ad libitum.
- 30 pigs were infected with SIV on study day 0.10 pigs were allocated to each of the three groups A, B, and C. Treatment (groups A and B) started after SIV challenge on the same day.
- The study animals were clinically examined daily on
study days 0 to 7 and 14. They were weighed onstudy days study day 7; the remaining study animals, group B and 5 study animals of group C, onstudy day 14. - It is the major finding of this study that meloxicam granules administered continuously in the drinking water at an approximate daily dose of 0.8 mg/kg body weight significantly alleviated the development of lung lesions caused by experimental infection with SIV during the first week after challenge.
FIG. 2 shows the quantity of lung lesions by lung lobe onstudy days - On
study day 7 the percentage of lung tissue affected with SIV-related lesions (median value) was 8.9% in meloxicam group A and 23.8% in the control group (5 study animals of group C). - Moreover, meloxicam-treated pigs reached significantly higher weight gains during the two weeks following infection than untreated controls. Mean daily weight gain in the
interval study day 0 to 7 was 557 g in meloxicam group A and 257 g in the control (5 study animals of group C). In theinterval study day 0 to 14, mean daily weight gain was 629 g in meloxicam group B and 486 g in the control (5 study animals of group C). - The area under the curve of the clinical index score (CIS), a sum of the relevant clinical parameters, over
study days 0 to 7 was significantly smaller in groups A and B than in group C. - Thus oral treatment with meloxicam granules at a dose of 0.8 mg meloxicam per kg body weight per day for 7 consecutive was an efficacious treatment for SIV infection.
- A medium scale farm (560 sows) with a previous history of recurring PRDC episodes was selected. A double-blinded randomized study was carried out with the selection of 162 growing animals with a mean age of 90 days at the onset of PRDC clinical signs. Animals were randomly allocated to 8 pens and divided into two treatment groups, with respect to equal sex ratio, same housing and feeding conditions and genetic background. Group 1 (PC) received 800 ppm chlorotetracycline in the feed over 8 consecutive days plus a single IM injection of a placebo (isotonic saline) at d0 (start of the trial, n=82). Group 2 (M) received 800 ppm chlorotetracycline in the teed over 8 consecutive days plus a single IM injection of 0.4 mg/kg bodyweight meloxicam (METACAM® 2%, Boehringer Ingelheim GmbH) at d0 (n=80). Clinical parameters were assessed as the daily Respiratory Score (RS), using a 3 point score (0=absence of signs to 3=abdominal breathing and disordered general condition) over 8 consecutive days and the total number of additional required injectable medications (AIM). Growth performance data for each group included the Average Daily Gain (ADG) for the following trial periods: d90 to d117, d117 to d170 (slaughtering), and d90 to d170 of age. Mortality was also calculated for these time periods. Slaughterhouse records per group, included the percentage of each lung surface (LS) affected by chronic and acute respiratory lesions.
- Student's t-Test and Pearson's Chi-Square Test were used for the consequent comparisons of means and frequencies between trial groups.
- RS and AIM in the meloxicam group were significantly lower (p<0.05) compared to the control group. Same applies for LS affected by acute lesions (p<0.01), while no differences were observed for LS in chronic cases (Table 1).
-
TABLE 1 RS, LS: Mean (SD); AIM number (%) Treatment Group PC M Significance RS 0.70 (0.63)a 0.50 (0.51)b p = 0.0289 AIM (%) 10/82 (12.2%)a 2/80 (2.5%)b x2 = 4.226 LS(chronic) 5.96 (2.28)a 5.91 (2.32)a p = 0.893 LS (acute) 3.71 (1.81)a 2.64 (2.03)b p = 0.0007 a,bValues in a row with different superscripts differ significantly - The analysis of growth performance data revealed significant differences between groups at d90 to d117 (p<0.05, Table 2).
-
TABLE 2 ADG: Mean (SD) Trial Period Group d90 to d117 d117 to d170 d90 to d170 PC 0.64 (0.09)a 0.89 (0.06)a 0.81 (0.03)a M 0.67 (0.10)b 0.89 (0.06)a 0.82 (0.03)a a,bValues in a column with different superscripts differ significantly (p < 0.05) -
TABLE 3 Mortality: Number of animals/group (%) Trial Period Group d90 to d117 d117 to d170 d90 to d170 PC 6/82 (7.32%)a 1/76 (1.22%) 7/82 (8.54%) M 0/80 (0.00%)b 1/80 (1.25%) 1/80 (1.25%) a,bValues in a column with different superscripts differ significantly (p < 0.05) - Under the conditions of this study, the reduction of the prevalence of respiratory signs as well as the reduced overall number of required injectable antibiotic medications are indicative for the potent anti-inflammatory activity of meloxicam. The latter could become a valuable adjunctive measure, especially when respiratory distress is associated with remarkable reduction of the feed intake. The initial differences in growth performance and in mortality rate could be explained by the fact that meloxicam, when combined with proper antimicrobial medication, contributes to faster recovery from a respiratory inflammation and faster restoring of the distorted growth rate of affected animals. Further research on the evaluation of feed intake and the use of meloxicam in PRDC recurring episodes is required.
Claims (22)
1. A method of treating or preventing a respiratory disease in a pig, the method comprising administering to the pig in need thereof an effective amount of the pharmaceutical composition of claim 23 .
2. The method according to claim 1 , wherein said pharmaceutical composition is administered systemically or orally.
3. The method according to claim 1 , wherein said pharmaceutical composition is administered in a daily dose ranging from 0.01 mg/kg to 5.0 mg/kg.
4. The method according to claim 2 , wherein said pharmaceutical composition is administered in a daily dose ranging from 0.01 mg/kg to 5.0 mg/kg.
5. The method according to claim 1 , wherein said pharmaceutical composition is administered by injection.
6. The method according to claim 2 , wherein said pharmaceutical composition is administered by injection.
7. The method according to claim 1 , wherein said pharmaceutical composition is administered via drinking water or as top dressing on feed in soluble granules.
8. The method according to claim 2 , wherein said pharmaceutical composition is administered via drinking water or as top dressing on feed in soluble granules.
9-10. (canceled)
11. The method according to claim 1 , wherein the antibiotic in the pharmaceutical composition of claim 23 is selected from the group consisting of β-lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides.
12. The method according to claim 2 , wherein the antibiotic in said pharmaceutical composition of claim 23 is selected from the group consisting of β-lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides.
13. The method according to claim 1 , wherein the antibiotic in said pharmaceutical composition of claim 23 is oxytetracycline or chlorotetracycline.
14. The method according to claim 2 , wherein the antibiotic in said pharmaceutical composition of claim 23 is oxytetracycline or chlorotetracycline.
15. The method according to claim 1 , wherein the disease is Porcine Respiratory Disease Complex and the pig is a growing or fattening pig.
16. The method according to claim 2 , wherein the disease is Porcine Respiratory Disease Complex and the pig is a growing or fattening pig.
17. The method according to claim 1 , wherein the disease is caused by mycoplasmas, bacteria, or viruses.
18. The method according to claim 2 , wherein the disease is caused by mycoplasmas, bacteria, or viruses.
19. The method according to claim 1 , wherein the disease is caused by Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Arcanobacterium pyogenes, Swine Influenza Virus, Aujetzky's Virus, Porcine Reproductive and Respiratory Syndrome Virus, Porcine Circovirus, and Transmissible Gastroenteritis and Porcine Respiratory Coronavirus.
20. The method according to claim 2 , wherein the disease is caused by Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Arcanobacterium pyogenes, Swine Influenza Virus, Aujetzky's Virus, Porcine Reproductive and Respiratory Syndrome Virus, Porcine Circovirus, and Transmissible Gastroenteritis and Porcine Respiratory Coronavirus.
21. The method according to claim 1 , wherein the disease is caused by Actinobacillus spp., Streptococcus spp., or Staphylococcus spp.
22. The method according to claim 2 , wherein the disease is caused by Actinobacillus spp., Streptococcus spp., or Staphylococcus spp.
23. A ready-to-use two-component pharmaceutical composition for the treatment of respiratory diseases in pigs, the composition comprising:
(a) a first component comprising meloxicam or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; and
(b) a second component comprising one or more antibiotics selected from the group consisting of β-lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides, and a pharmaceutically acceptable carrier.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/114,509 US20080280840A1 (en) | 2004-02-23 | 2008-05-02 | Meloxicam for the treatment of respiratory diseases in pigs |
US14/183,744 US20140179639A1 (en) | 2004-02-23 | 2014-02-19 | Meloxicam for the treatment of respiratory diseases in pigs |
US15/908,470 US10548901B2 (en) | 2004-02-23 | 2018-02-28 | Meloxicam for the treatment of respiratory diseases in pigs |
US16/719,681 US11083731B2 (en) | 2004-02-23 | 2019-12-18 | Meloxicam for the treatment of respiratory diseases in pigs |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04004054A EP1568369A1 (en) | 2004-02-23 | 2004-02-23 | Use of meloxicam for the treatment of respiratory diseases in pigs |
EPEP04004054.5 | 2004-02-23 | ||
US11/047,920 US20050187213A1 (en) | 2004-02-23 | 2005-02-01 | Meloxicam for the treatment of respiratory diseases in pigs |
US12/114,509 US20080280840A1 (en) | 2004-02-23 | 2008-05-02 | Meloxicam for the treatment of respiratory diseases in pigs |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/047,920 Continuation US20050187213A1 (en) | 2004-02-23 | 2005-02-01 | Meloxicam for the treatment of respiratory diseases in pigs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/183,744 Division US20140179639A1 (en) | 2004-02-23 | 2014-02-19 | Meloxicam for the treatment of respiratory diseases in pigs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080280840A1 true US20080280840A1 (en) | 2008-11-13 |
Family
ID=34745861
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/047,920 Abandoned US20050187213A1 (en) | 2004-02-23 | 2005-02-01 | Meloxicam for the treatment of respiratory diseases in pigs |
US12/114,509 Abandoned US20080280840A1 (en) | 2004-02-23 | 2008-05-02 | Meloxicam for the treatment of respiratory diseases in pigs |
US14/183,744 Abandoned US20140179639A1 (en) | 2004-02-23 | 2014-02-19 | Meloxicam for the treatment of respiratory diseases in pigs |
US15/908,470 Active US10548901B2 (en) | 2004-02-23 | 2018-02-28 | Meloxicam for the treatment of respiratory diseases in pigs |
US16/719,681 Active US11083731B2 (en) | 2004-02-23 | 2019-12-18 | Meloxicam for the treatment of respiratory diseases in pigs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/047,920 Abandoned US20050187213A1 (en) | 2004-02-23 | 2005-02-01 | Meloxicam for the treatment of respiratory diseases in pigs |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/183,744 Abandoned US20140179639A1 (en) | 2004-02-23 | 2014-02-19 | Meloxicam for the treatment of respiratory diseases in pigs |
US15/908,470 Active US10548901B2 (en) | 2004-02-23 | 2018-02-28 | Meloxicam for the treatment of respiratory diseases in pigs |
US16/719,681 Active US11083731B2 (en) | 2004-02-23 | 2019-12-18 | Meloxicam for the treatment of respiratory diseases in pigs |
Country Status (16)
Country | Link |
---|---|
US (5) | US20050187213A1 (en) |
EP (2) | EP1568369A1 (en) |
JP (1) | JP5009147B2 (en) |
KR (1) | KR101233359B1 (en) |
CN (1) | CN1921865B (en) |
AU (1) | AU2005215122B2 (en) |
BR (1) | BRPI0507966A (en) |
CA (1) | CA2554040C (en) |
DK (1) | DK1720554T3 (en) |
ES (1) | ES2394038T3 (en) |
MX (1) | MXPA06009575A (en) |
RU (1) | RU2360680C2 (en) |
SG (1) | SG150531A1 (en) |
TW (1) | TW200533362A (en) |
UA (1) | UA92584C2 (en) |
WO (1) | WO2005079806A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040180092A1 (en) * | 2002-10-25 | 2004-09-16 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
US20050245510A1 (en) * | 2004-04-29 | 2005-11-03 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam formulations in veterinary medicine |
US20050288280A1 (en) * | 2004-06-23 | 2005-12-29 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam in veterinary medicine |
US20060079516A1 (en) * | 2000-06-20 | 2006-04-13 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions |
US20070077296A1 (en) * | 2005-09-30 | 2007-04-05 | Folger Martin A | Pharmaceutical Preparation containing Meloxicam |
US20080132493A1 (en) * | 2001-12-12 | 2008-06-05 | Martin Andreas Folger | Highly concentrated stable meloxicam solutions for needleless injection |
US20110083985A1 (en) * | 2009-10-12 | 2011-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
US9149480B2 (en) | 2010-03-03 | 2015-10-06 | Boehringer Ingeleheim Vetmedica GmbH | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
US10548901B2 (en) | 2004-02-23 | 2020-02-04 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam for the treatment of respiratory diseases in pigs |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100643222B1 (en) | 2005-09-01 | 2006-11-10 | 빙빙투기술 주식회사 | Therapeutic compostion for postweaning multisystemic wasting syndrome |
EP1870102A1 (en) * | 2006-06-15 | 2007-12-26 | Alpex Pharma SA | Solid forms containing meloxicam with improved taste and process for their preparation |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8097419B2 (en) * | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US20090098527A1 (en) * | 2006-09-12 | 2009-04-16 | Fischer Gerald W | Biological organism identification product and methods |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
KR100870077B1 (en) | 2006-10-27 | 2008-11-25 | 권영득 | Pharmaceutical formulation in the treatment of PMWS |
BRPI0700969A (en) | 2007-03-22 | 2008-11-04 | Ouro Fino Participacoes E Empr | composition for the treatment of bacterial and inflammatory conditions in pet animals |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
RU2468034C2 (en) * | 2007-08-27 | 2012-11-27 | ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
EP2535428B1 (en) | 2007-10-01 | 2015-09-09 | Longhorn Vaccines and Diagnostics, LLC | Biological specimen collection and transport system and methods of use |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
US20110092454A1 (en) * | 2009-09-30 | 2011-04-21 | Dean Rimoldi | Methods For Treating Mycoplasma Related Conditions In Livestock |
US8791105B2 (en) | 2010-07-14 | 2014-07-29 | Kansas State University Research Foundation | Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration |
CN104203272A (en) | 2012-01-26 | 2014-12-10 | 长角牛疫苗和诊断有限责任公司 | Composite antigenic sequences and vaccines |
GB2520065A (en) * | 2013-11-08 | 2015-05-13 | Norbrook Lab Ltd | Tulathromycin and nonsteroidal anti-inflammatory drug compositions |
EP2995297A1 (en) * | 2014-09-09 | 2016-03-16 | Ceva Sante Animale | Parenteral compositions and uses thereof |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
CA3069400A1 (en) * | 2017-07-20 | 2019-01-24 | National University Corporation Hokkaido University | Combination use of inhibitor targeting pd-1/pd-l1 and cox-2 inhibitor |
WO2021151264A1 (en) * | 2020-01-30 | 2021-08-05 | 沈阳福洋医药科技有限公司 | Use of acylated spiramycin in preparation of medicament for treating coronavirus infectious disease |
Citations (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2795529A (en) * | 1954-06-17 | 1957-06-11 | American Home Prod | Stabilized hyaluronidase solution containing calcium chloride |
US3288675A (en) * | 1964-03-20 | 1966-11-29 | Hoffmann La Roche | Parenteral sulfonamide compositions and processes |
US3849549A (en) * | 1971-10-06 | 1974-11-19 | Merck & Co Inc | Indomethacin suppositories |
US3931212A (en) * | 1973-07-19 | 1976-01-06 | Warner-Lambert Company | Method for treating cardiovascular circulatory insufficiencies and hypotonia with 2-hydroxy-phenyl-1-oxa-4-azaspiroalkane derivatives |
US3947576A (en) * | 1973-09-27 | 1976-03-30 | Mortell Company | Synergistic biostatic composition |
US4233299A (en) * | 1977-12-16 | 1980-11-11 | Boehringer Ingelheim Gmbh | 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides and salts thereof |
US4482554A (en) * | 1982-05-08 | 1984-11-13 | Warner-Lambert Company | Pharmaceutical compositions containing oxicam derivatives and process for their preparation |
US4543200A (en) * | 1983-09-28 | 1985-09-24 | Sherman Laboratories, Inc. | Contact lens preservative system cleaner and method |
US4628053A (en) * | 1984-10-10 | 1986-12-09 | Heinrich Mack Nachf. | Stabilized injectable solutions of piroxicam |
US4748174A (en) * | 1986-01-03 | 1988-05-31 | Therapicon S.R.L. | Water soluble salts of an NSAID with meglumine/glucamine |
US4794117A (en) * | 1984-03-03 | 1988-12-27 | Jerome Corbiere | Process for solubilizing active ingredients and the thus-obtained pharmaceutical compositions |
US4802926A (en) * | 1986-03-21 | 1989-02-07 | Dmv-Campina B.V. | Spray dried lactose and process for preparing the same |
US4835187A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
US4942167A (en) * | 1988-04-01 | 1990-07-17 | Chiesi Farmaceutici S.P.A. | Pharmaceutical compositions of piroxicam in aqueous solutions and process for their preparation |
US5169847A (en) * | 1990-11-27 | 1992-12-08 | Egis Gyogyszergyar | Drug solutions of increased stability and without tissue-damaging effect and process for preparing same |
US5283065A (en) * | 1989-09-21 | 1994-02-01 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
US5304561A (en) * | 1992-07-24 | 1994-04-19 | Faezeh Sarfarazi | New concept in glaucoma treatment |
US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
US5380934A (en) * | 1992-10-29 | 1995-01-10 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing alanylgutamine |
US5414011A (en) * | 1987-09-11 | 1995-05-09 | Syntex (U.S.A.) Inc. | Preservative system for ophthalmic formulations |
US5654003A (en) * | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US5824658A (en) * | 1990-09-18 | 1998-10-20 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
US5886030A (en) * | 1994-05-06 | 1999-03-23 | Alcon Laboratories, Inc. | Use of vitamin E tocopheryl derivatives in ophthalmic compositions |
US5962012A (en) * | 1997-11-28 | 1999-10-05 | Caleb Pharmaceuticals, Inc. | Cholinergic antagonist patch |
US6046191A (en) * | 1997-10-10 | 2000-04-04 | Astra Pharmaceuticals Ltd. | Combination |
US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
US6156349A (en) * | 1998-12-14 | 2000-12-05 | Steinbach, Pylant And Herman, L.L.C. | Method of treating HIV infection with suppository containing mammalian liver extract |
US6166012A (en) * | 1999-07-30 | 2000-12-26 | Allergan Sales, Inc. | Antibiotic compositions and method for using same |
US6180136B1 (en) * | 1998-11-10 | 2001-01-30 | Idexx Laboratories, Inc. | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
US6183779B1 (en) * | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
US6184220B1 (en) * | 1998-03-27 | 2001-02-06 | Boehringer Ingelheim Pharma Kg | Oral suspension of pharmaceutical substance |
US6187800B1 (en) * | 1996-06-20 | 2001-02-13 | Novartis Animal Health U.S., Inc. | Method for the prevention and treatment of mastitis |
US6221377B1 (en) * | 1995-11-13 | 2001-04-24 | Pitmy International N.V. | Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs |
US6284269B1 (en) * | 1997-08-27 | 2001-09-04 | Hexal Ag | Pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
US6319519B2 (en) * | 1998-07-07 | 2001-11-20 | Norton Healthcare Ltd. | Anti-inflammatory pharmaceutical formulations |
US20020006440A1 (en) * | 2000-07-05 | 2002-01-17 | Cherukuri Subraman Rao | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
US20020016342A1 (en) * | 2000-05-15 | 2002-02-07 | Edward Scolnick | Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
US20020035107A1 (en) * | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
US20020068088A1 (en) * | 1996-08-15 | 2002-06-06 | Peter Gruber | Easy to swallow oral medicament composition |
US20020077328A1 (en) * | 2000-07-13 | 2002-06-20 | Fred Hassan | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain |
US20020099049A1 (en) * | 1997-09-17 | 2002-07-25 | Burch Ronald M. | Analgesic combination of oxycodone and meloxicam |
US20020106345A1 (en) * | 1999-12-07 | 2002-08-08 | Uhrich Kathryn E. | Therapeutic compositions and methods |
US20020187187A1 (en) * | 2001-04-21 | 2002-12-12 | Toshimitsu Ohki | Fast disintegrating meloxicam tablet |
US6495603B1 (en) * | 1998-05-15 | 2002-12-17 | Wakamoto Pharmaceutical Co., Ltd. | Anti-inflammatory eye drop |
US20030050305A1 (en) * | 2000-05-22 | 2003-03-13 | Tejada Inigo Saenz De | Thromboxane inhibitors, compositions and methods of use |
US20030055051A1 (en) * | 1999-11-24 | 2003-03-20 | Wakamoto Pharmaceutical Co., Ltd. | Ophthalmic aqueous pharmaceutical preparation |
US6550955B2 (en) * | 2000-05-03 | 2003-04-22 | D'silva Joe | Process for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules using a mixing cup with an abrasive interior surface |
US20030109701A1 (en) * | 2001-12-11 | 2003-06-12 | Laura Coppi | Crystalline forms of meloxicam and processes for their preparation and interconversion |
US20030119825A1 (en) * | 2001-12-12 | 2003-06-26 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions for needleless injection |
US6599529B1 (en) * | 1997-09-11 | 2003-07-29 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs) |
US6605295B1 (en) * | 1997-07-11 | 2003-08-12 | Bausch & Lomb Incorporated | Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin |
US6630056B1 (en) * | 1997-07-10 | 2003-10-07 | Thibierge & Comar | Color tracing paper |
US20030199482A1 (en) * | 2001-03-28 | 2003-10-23 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
US20030220306A1 (en) * | 2001-09-28 | 2003-11-27 | Daniel Simmons | Novel cyclooxygenase variants and methods of use |
US6669957B1 (en) * | 1999-09-15 | 2003-12-30 | Cll Pharma | Galenic formulations fast disintegrating in the mouth and method for preparing same |
US20040001883A1 (en) * | 2002-03-30 | 2004-01-01 | Boehringer Ingelheim International Gmbh | Meloxicam suppositories |
US20040024042A1 (en) * | 2002-04-02 | 2004-02-05 | Vanderbilt University | COX2 inhibition in the prevention and treatment of autosomal dominant polycystic kidney disease |
US20040024041A1 (en) * | 2000-07-01 | 2004-02-05 | Torsten Selzer | Dermal therapeutic system containing non-steroidal antiphlogistics with selective cox-2 inhibition |
US20040037869A1 (en) * | 2002-08-16 | 2004-02-26 | Douglas Cleverly | Non-animal product containing veterinary formulations |
US20040043992A1 (en) * | 2002-05-22 | 2004-03-04 | Boehringer Ingelheim International Gmbh | Meloxicam for alleviating organ injury during organ operation or transplantation |
US20040110747A1 (en) * | 2002-12-06 | 2004-06-10 | Boehringer Ingelheim International Gmbh | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
US20040171611A1 (en) * | 2002-09-30 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline acetic acid solvate of meloxicam |
US20040180092A1 (en) * | 2002-10-25 | 2004-09-16 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
US20040198826A1 (en) * | 2003-04-07 | 2004-10-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination for treating benign prostatic hyperplasia or for treating abacterial prostatitis |
US20040204413A1 (en) * | 2001-01-26 | 2004-10-14 | Joaquina Faour | Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant |
US20040204472A1 (en) * | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
US20040214753A1 (en) * | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
US20040229038A1 (en) * | 2003-03-03 | 2004-11-18 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
US20050038018A1 (en) * | 2003-07-09 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Meloxicam compositions |
US6869948B1 (en) * | 1998-03-27 | 2005-03-22 | Boehringer Ingelheim Pharma Kg | Meloxicam for oral administration |
US20050147664A1 (en) * | 2003-11-13 | 2005-07-07 | Elan Pharma International Ltd. | Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery |
US20050187213A1 (en) * | 2004-02-23 | 2005-08-25 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam for the treatment of respiratory diseases in pigs |
US20050187212A1 (en) * | 2002-09-17 | 2005-08-25 | Nippon Boehringer Ingelheim Co., Ltd. | Pharmaceutical composition for topical delivery of meloxicam |
US20050197332A1 (en) * | 2002-12-10 | 2005-09-08 | Boehringer Ingelheim International | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
US20050245510A1 (en) * | 2004-04-29 | 2005-11-03 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam formulations in veterinary medicine |
US20050277634A1 (en) * | 2004-05-19 | 2005-12-15 | Boehringer Ingelheim Vetmedica Gmbh | Liquid composition for veterinary medicine and process for the preparation and use thereof |
US20050288280A1 (en) * | 2004-06-23 | 2005-12-29 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam in veterinary medicine |
US6986346B2 (en) * | 1998-10-17 | 2006-01-17 | Boehringer Ingelheim Pharma Kg | Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
US20060217431A1 (en) * | 2005-03-23 | 2006-09-28 | Boehringer Ingelheim International Gmbh | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor |
US20070077296A1 (en) * | 2005-09-30 | 2007-04-05 | Folger Martin A | Pharmaceutical Preparation containing Meloxicam |
US20080234380A1 (en) * | 1992-06-30 | 2008-09-25 | Shapiro Howard K | Compositions and method for treatment of chronic inflammatory diseases |
US7969206B2 (en) * | 2007-05-21 | 2011-06-28 | Denso Corporation | Semiconductor element drive circuit |
US20110275618A1 (en) * | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim Vetmedica Gmbh | Novel low concentration meloxicam tablets |
US20120077764A1 (en) * | 2003-05-29 | 2012-03-29 | Freehauf Keith A | Compositions and method for treating infection in cattle and swine |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3089818A (en) | 1960-06-02 | 1963-05-14 | Baxter Laboratories Inc | Water dispersible antibiotics |
JPS477352Y1 (en) | 1969-06-13 | 1972-03-17 | ||
JPS52102416A (en) | 1976-02-19 | 1977-08-27 | Okawara Mfg | Granule making method of herb medicine and like |
FR2437838A1 (en) | 1978-07-25 | 1980-04-30 | Roecar Holdings Nv | Prostaglandin inhibitors for benign adenoma of the prostate - includes salicylic, anthranilic and phenylacetic acid derivs., indole(s), indene(s), pyrrole(s) and pyrazolidine(s) |
IE49770B1 (en) | 1979-05-21 | 1985-12-11 | Leo Pharm Prod Ltd | 6beta-halopenicillanic acid derivatives |
JPS56110665A (en) | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
IE51846B1 (en) | 1980-11-17 | 1987-04-15 | Leo Pharm Prod Ltd | Pharmaceutical preparation for veterinary use and an appliance containing it |
US4447443A (en) | 1982-11-15 | 1984-05-08 | Merck & Co., Inc. | Anti-inflammatory/analgesic combination of α-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID) |
EP0127400A3 (en) | 1983-05-31 | 1986-06-11 | Stauffer Chemical Company | Magnesium oxide containing vehicle for direct compression tableting |
IT1212778B (en) | 1983-10-07 | 1989-11-30 | Lisapharma Spa | PHARMACEUTICAL COMPOSITIONS ANTI-INFLAMMATORY AND / OR ANALGESIC ADAPTERITY, NON ULCEROGENE. |
JPH0753663B2 (en) | 1984-10-09 | 1995-06-07 | 武田薬品工業株式会社 | Thiamine salt granules, their production and tablets |
IT1196307B (en) | 1984-10-22 | 1988-11-16 | Chiesi Farma Spa | AQUEOUS PHARMACEUTICAL FORMULATIONS OF PIROXICAM MONOHYDRATE |
US4687662A (en) | 1985-08-30 | 1987-08-18 | Warner-Lambert Company | Therapeutic effervescent composition |
SE8605515D0 (en) | 1986-12-22 | 1986-12-22 | Astra Laekemedel Ab | A LIQUID DOSAGE FORM FOR ORAL ADMINISTRATION OF A PHARMACEUTICALLY ACTIVE SUBSTANCE |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
IL83086A (en) | 1987-07-06 | 1991-03-10 | Teva Pharma | Stable,injectable solutions of vincristine salts |
JPH0696542B2 (en) | 1987-09-11 | 1994-11-30 | シンテックス(ユー・エス・エイ)インコーポレイテッド | Ophthalmic preservative formulation and method for producing the same |
ATE103599T1 (en) | 1988-09-21 | 1994-04-15 | Searle & Co | 3-OXIRANBENZOACIDS AND DERIVATIVES. |
ATE107854T1 (en) | 1988-09-30 | 1994-07-15 | Rhone Poulenc Rorer Ltd | PHARMACEUTICAL GRANULES. |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
IL95942A0 (en) | 1989-10-13 | 1991-07-18 | Syntex Inc | Collagen-containing ophthalmic formulation |
KR920002148A (en) | 1990-07-03 | 1992-02-28 | 안드레아 엘. 콜비 | Pharmaceutical compositions for alleviating gastrointestinal symptoms caused by nonsteroidal anti-inflammatory drugs and methods for alleviating the same |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
SK282072B6 (en) | 1991-01-30 | 2001-10-08 | The Wellcome Foundation Limited | Water-dispersible tablet containing lamotrigine and its preparation method |
JP3541849B2 (en) | 1991-04-19 | 2004-07-14 | 久光製薬株式会社 | Anti-inflammatory analgesic patch |
FR2679135B1 (en) | 1991-07-18 | 1995-05-19 | Europhta Sa Laboratoire | NOVEL OPHTHALMIC COMPOSITIONS WITH IMPROVED ADHESIVITY AND METHODS OF PREPARING THE SAME. |
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
IT1251650B (en) | 1991-10-29 | 1995-05-17 | Boehringer Ingelheim Italia | Inclusion compounds of meloxicam with cyclodextrin |
JP2860729B2 (en) | 1992-03-10 | 1999-02-24 | エスエス製薬株式会社 | Planoprofen suspension syrup |
DE4217971C1 (en) | 1992-05-30 | 1993-10-21 | Boehringer Ingelheim Vetmed | Process and fluid bed apparatus for granulating and / or wrapping |
US5455271A (en) | 1992-06-18 | 1995-10-03 | The Scripps Research Institute | Tight-binding inhibitors of leukotriene A4 hydrolase |
KR0169505B1 (en) | 1992-09-11 | 1999-01-15 | 오오쓰끼 아끼히꼬 | Drug packing polyolefinic material, process for producing the same and container for drug packing |
JPH06157312A (en) | 1992-11-12 | 1994-06-03 | Shionogi & Co Ltd | Bitterness-improved dry syrup granule of terfenadine |
IT1264020B (en) | 1993-01-28 | 1996-09-09 | Recordati Chem Pharm | PROCEDURE FOR THE PREPARATION OF MICROGRANULES SUITABLE FOR SUSPENSION IN LIQUIDS |
ES2065846B1 (en) | 1993-04-20 | 1995-10-01 | Cusi Lab | PHARMACEUTICAL FORMULATION BASED ON A STEROID OR NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTIBIOTIC BELONGING TO THE GIRASE DNA INHIBITORS GROUP FOR ITS TOPICAL OPHTHALMIC USE. |
DE4322826A1 (en) | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmaceutical preparation |
US5676944A (en) | 1993-10-06 | 1997-10-14 | The Regents Of The University Of California | Ocular therapy with homologous macrophages |
US5474985A (en) | 1993-12-22 | 1995-12-12 | The Regents Of The University Of California | Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors |
WO1995018604A1 (en) | 1994-01-11 | 1995-07-13 | Ciba-Geigy Ag | Topical treatment of ocular photophobia |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5585492A (en) | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
JP3550782B2 (en) | 1995-03-14 | 2004-08-04 | 大日本インキ化学工業株式会社 | Expandable particles of lactic acid-based polyester |
US5674888A (en) | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
US5599535A (en) | 1995-06-07 | 1997-02-04 | Regents Of The University Of California | Methods for the cyto-protection of the trabecular meshwork |
JPH0912426A (en) | 1995-06-29 | 1997-01-14 | Asahi Chem Ind Co Ltd | Hygroscopic material composition |
DE69632632T2 (en) | 1995-07-19 | 2005-05-25 | Merck & Co., Inc. | TREATMENT PROCEDURE FOR DARMADENOMES |
EP0839029A1 (en) | 1995-07-20 | 1998-05-06 | PHARMACIA & UPJOHN COMPANY | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
FR2739562B1 (en) | 1995-10-09 | 1998-04-24 | Moreau Defarges Alain | JET INJECTION DEVICE WITHOUT NEEDLE, INCLUDING AN OVER-MOLDED CARTRIDGE |
US5686414A (en) | 1995-11-14 | 1997-11-11 | Xoma Corporation | Methods of treating conditions associated with corneal transplantation |
ATE210461T1 (en) | 1996-02-13 | 2001-12-15 | Searle & Co | COMPOSITIONS WITH IMMUNOSUPPRESSIVE EFFECTS CONTAINING 5-LIPOXYGENASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS |
EP0889724A1 (en) | 1996-02-27 | 1999-01-13 | Rpms Technology Limited | Cox-2 selective inhibitors for managing labour and uterine contractions |
US6048557A (en) | 1996-03-26 | 2000-04-11 | Dsm N.V. | PUFA coated solid carrier particles for foodstuff |
ATA156496A (en) | 1996-09-03 | 1997-10-15 | Nycomed Austria Gmbh | PHARMACEUTICAL COMPOSITION |
GB2318511A (en) | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
CA2277100C (en) | 1997-01-06 | 2005-11-22 | Pfizer Inc. | Cyclic sulfone derivatives |
CN1062161C (en) | 1997-01-08 | 2001-02-21 | 大连弘丰制药厂 | Stable prescription and process of fleabane extract injection |
FR2758459B1 (en) | 1997-01-17 | 1999-05-07 | Pharma Pass | FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME |
US5954104A (en) | 1997-02-28 | 1999-09-21 | Abbott Laboratories | Container cap assembly having an enclosed penetrator |
NZ335364A (en) | 1997-03-26 | 2000-08-25 | Janssen Pharmaceutica Nv | Pellets having a core 250-355 um coated with an antifungal and a polymer, pharmaceutical, and process |
TR199902748T2 (en) | 1997-05-06 | 2000-05-22 | Norbrook Laboratories Limited | Advances in long-acting antimicrobial agents |
JP4936579B2 (en) | 1997-09-05 | 2012-05-23 | 第一三共株式会社 | Loxoprofen-containing pharmaceutical preparation |
GB9726701D0 (en) | 1997-12-18 | 1998-02-18 | Merck Sharp & Dohme | Therapeutic use |
AU749006B2 (en) | 1997-12-03 | 2002-06-13 | Merck Sharp & Dohme Corp. | Long acting injectable formulations containing hydrogenated castor oil |
WO1999039730A1 (en) | 1998-02-09 | 1999-08-12 | Kaken Pharmaceutical Co., Ltd. | Oral preparations containing peptides promoting the secretion of growth hormone |
EP0945131A1 (en) | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Peroral drug suspension |
ATE269069T1 (en) | 1998-04-29 | 2004-07-15 | Sumitomo Pharma | ORAL PREPARATION CONTAINING A BIGUANIDE AND AN ORGANIC ACID |
US6132758A (en) | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
EP1109534B1 (en) | 1998-09-10 | 2003-02-12 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
GB9823246D0 (en) | 1998-10-24 | 1998-12-16 | Danbiosyst Uk | A nasal drug delivery composition |
FR2796840B1 (en) | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | LOW-DOSE TABLETS AND METHOD OF PREPARATION |
US6552020B1 (en) | 1999-07-30 | 2003-04-22 | Allergan, Inc. | Compositions including antibiotics and methods for using same |
TR200200313T2 (en) | 1999-08-17 | 2002-04-22 | Novartis Consumer Health S.A. | Rapidly dissolving dosage form and its production process. |
KR200182299Y1 (en) | 1999-12-08 | 2000-05-15 | 장지일 | Floss holder having floss case |
JP2001172183A (en) | 1999-12-21 | 2001-06-26 | Wakamoto Pharmaceut Co Ltd | Ophthalmic pharmaceutical composition |
IN191512B (en) | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
US6689092B2 (en) | 2000-03-03 | 2004-02-10 | Boehringer International Gmbh | Needle-less injector of miniature type |
DE10010123A1 (en) | 2000-03-03 | 2001-09-20 | Boehringer Ingelheim Int | Needle-less injector for liquids comprises a tensioning system, an energy storing spring, a hollow piston in a cylinder, and a nozzle |
DE10024752A1 (en) | 2000-05-16 | 2001-11-29 | Ben Pfeifer | Composition for treating prostate diseases, especially inflammation, hyperplasia or cancer, comprises active agent solution containing dimethyl sulfoxide or hyaluronidase as diffusion promoter, applied using catheter |
DE10030345A1 (en) * | 2000-06-20 | 2002-01-10 | Boehringer Ingelheim Vetmed | Highly concentrated stable meloxicam solutions |
GB0022215D0 (en) | 2000-09-11 | 2000-10-25 | Boehringer Ingelheim Pharma | Method for the treatment of thromboembolic disorders in patients with aspirin« resistance |
US6787568B1 (en) | 2000-11-27 | 2004-09-07 | Phoenix Scientific, Inc. | Antibiotic/analgesic formulation and a method of making this formulation |
ATE398175T1 (en) * | 2000-12-08 | 2008-07-15 | Coley Pharmaceuticals Gmbh | CPG-TYPE NUCLEIC ACIDS AND METHODS OF USE THEREOF |
DE10300323A1 (en) | 2003-01-09 | 2004-10-14 | Baxter Healthcare S.A. | Safety container filled with a biologically active substance, especially a cytostatic agent, is at least partially coated |
US6995190B2 (en) | 2001-03-09 | 2006-02-07 | Veterinary Solutions | Method and treatment with ketoprofen solution |
EP1250921A1 (en) | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
AUPR527801A0 (en) | 2001-05-25 | 2001-06-21 | University Of Sydney, The | Animal husbandry iii |
EP1348436A1 (en) | 2002-03-30 | 2003-10-01 | Boehringer Ingelheim International GmbH | Meloxicam suppositories |
WO2004004776A1 (en) | 2002-07-09 | 2004-01-15 | B.M.R.A. Corporation B.V. | Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
WO2004026116A2 (en) | 2002-09-19 | 2004-04-01 | The Regents Of The University Of California | Use of etodoclac to treat hyperplasia |
DE10250081A1 (en) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
US20040170687A1 (en) | 2003-02-27 | 2004-09-02 | Integrity Pharmaceutical Corporation | Compositions with improved stability and methods of formulation thereof |
DE10315702A1 (en) | 2003-04-07 | 2004-10-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of drug combinations for the treatment of benign prostatic hyperplasia or for the treatment of abacterial prostatitis |
JP4018022B2 (en) | 2003-04-10 | 2007-12-05 | 株式会社ホシモト | Opening and closing handle device |
US20050159419A1 (en) | 2003-05-14 | 2005-07-21 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage |
WO2005004915A2 (en) | 2003-07-09 | 2005-01-20 | Boehringer Ingelheim International Gmbh | Compositions comprising meloxicam |
CN1233323C (en) | 2003-12-09 | 2005-12-28 | 成都圣诺科技发展有限公司 | Orally disintegrating tablet of meloxicam and its preparation |
CA2562305A1 (en) | 2004-04-08 | 2005-10-20 | Idd-Eal Manufacturing Company Limited | Container for constituting a formulation in liquid form |
KR101406767B1 (en) | 2004-08-13 | 2014-06-20 | 베링거 인겔하임 인터내셔날 게엠베하 | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
ATE404206T1 (en) | 2004-12-06 | 2008-08-15 | Janssen Pharmaceutica Nv | ORAL SUSPENSION WITH MELOXICAM |
US7947348B2 (en) | 2005-12-20 | 2011-05-24 | Basell Poliolefine Italia, s.r.l. | Polypropylene compositions for stretched articles |
US20070187405A1 (en) | 2006-01-23 | 2007-08-16 | Pujara Chetan P | Container for compositions containing cefdinir |
JP4965130B2 (en) | 2006-01-26 | 2012-07-04 | 日本臓器製薬株式会社 | Dry type quick-disintegrating tablet |
US20070249727A1 (en) | 2006-04-21 | 2007-10-25 | The Proctor & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
ITMI20060983A1 (en) | 2006-05-18 | 2007-11-19 | Formevet S P A | VETERINARY PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND INFLAMMATION |
US20100015184A1 (en) | 2006-12-13 | 2010-01-21 | Tuel Stephen M | Methods of Making Pharmaceutical Components for Customized Drug Products |
BRPI0700969A (en) | 2007-03-22 | 2008-11-04 | Ouro Fino Participacoes E Empr | composition for the treatment of bacterial and inflammatory conditions in pet animals |
FR2917381B1 (en) | 2007-06-15 | 2009-10-16 | Ceva Sante Animale Sa | MULTILAYER PLASTIC PACKAGING FOR PRESERVING A PHARMACEUTICAL COMPOSITION |
CA2702261A1 (en) | 2007-10-12 | 2009-04-16 | Map Pharmaceuticals, Inc. | Inhalation drug delivery |
GB0724707D0 (en) | 2007-12-19 | 2008-01-30 | Burke Michael H | A process for the preparation of an orally administered unit dose tablet |
AU2010307096B2 (en) | 2009-10-12 | 2014-07-03 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
WO2011107150A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
US20110218191A1 (en) | 2010-03-03 | 2011-09-08 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long term-treatment of kidney disorders in cats |
-
2004
- 2004-02-23 EP EP04004054A patent/EP1568369A1/en not_active Withdrawn
-
2005
- 2005-02-01 US US11/047,920 patent/US20050187213A1/en not_active Abandoned
- 2005-02-16 UA UAA200610076A patent/UA92584C2/en unknown
- 2005-02-16 WO PCT/EP2005/001549 patent/WO2005079806A1/en active Application Filing
- 2005-02-16 CN CN2005800054227A patent/CN1921865B/en active Active
- 2005-02-16 JP JP2007500103A patent/JP5009147B2/en active Active
- 2005-02-16 MX MXPA06009575A patent/MXPA06009575A/en active IP Right Grant
- 2005-02-16 BR BRPI0507966-7A patent/BRPI0507966A/en not_active Application Discontinuation
- 2005-02-16 ES ES05707421T patent/ES2394038T3/en active Active
- 2005-02-16 DK DK05707421.3T patent/DK1720554T3/en active
- 2005-02-16 RU RU2006133829/15A patent/RU2360680C2/en not_active IP Right Cessation
- 2005-02-16 EP EP05707421A patent/EP1720554B1/en active Active
- 2005-02-16 CA CA2554040A patent/CA2554040C/en active Active
- 2005-02-16 SG SG200901183-4A patent/SG150531A1/en unknown
- 2005-02-16 KR KR1020067019671A patent/KR101233359B1/en active IP Right Grant
- 2005-02-16 AU AU2005215122A patent/AU2005215122B2/en active Active
- 2005-02-22 TW TW094105259A patent/TW200533362A/en unknown
-
2008
- 2008-05-02 US US12/114,509 patent/US20080280840A1/en not_active Abandoned
-
2014
- 2014-02-19 US US14/183,744 patent/US20140179639A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/908,470 patent/US10548901B2/en active Active
-
2019
- 2019-12-18 US US16/719,681 patent/US11083731B2/en active Active
Patent Citations (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2795529A (en) * | 1954-06-17 | 1957-06-11 | American Home Prod | Stabilized hyaluronidase solution containing calcium chloride |
US3288675A (en) * | 1964-03-20 | 1966-11-29 | Hoffmann La Roche | Parenteral sulfonamide compositions and processes |
US3849549A (en) * | 1971-10-06 | 1974-11-19 | Merck & Co Inc | Indomethacin suppositories |
US3931212A (en) * | 1973-07-19 | 1976-01-06 | Warner-Lambert Company | Method for treating cardiovascular circulatory insufficiencies and hypotonia with 2-hydroxy-phenyl-1-oxa-4-azaspiroalkane derivatives |
US3947576A (en) * | 1973-09-27 | 1976-03-30 | Mortell Company | Synergistic biostatic composition |
US4233299A (en) * | 1977-12-16 | 1980-11-11 | Boehringer Ingelheim Gmbh | 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides and salts thereof |
US4482554A (en) * | 1982-05-08 | 1984-11-13 | Warner-Lambert Company | Pharmaceutical compositions containing oxicam derivatives and process for their preparation |
US4543200A (en) * | 1983-09-28 | 1985-09-24 | Sherman Laboratories, Inc. | Contact lens preservative system cleaner and method |
US4794117A (en) * | 1984-03-03 | 1988-12-27 | Jerome Corbiere | Process for solubilizing active ingredients and the thus-obtained pharmaceutical compositions |
US4628053A (en) * | 1984-10-10 | 1986-12-09 | Heinrich Mack Nachf. | Stabilized injectable solutions of piroxicam |
US4748174A (en) * | 1986-01-03 | 1988-05-31 | Therapicon S.R.L. | Water soluble salts of an NSAID with meglumine/glucamine |
US4802926A (en) * | 1986-03-21 | 1989-02-07 | Dmv-Campina B.V. | Spray dried lactose and process for preparing the same |
US4835187A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
US5414011A (en) * | 1987-09-11 | 1995-05-09 | Syntex (U.S.A.) Inc. | Preservative system for ophthalmic formulations |
US4942167A (en) * | 1988-04-01 | 1990-07-17 | Chiesi Farmaceutici S.P.A. | Pharmaceutical compositions of piroxicam in aqueous solutions and process for their preparation |
US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
US5283065A (en) * | 1989-09-21 | 1994-02-01 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
US5824658A (en) * | 1990-09-18 | 1998-10-20 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
US5169847A (en) * | 1990-11-27 | 1992-12-08 | Egis Gyogyszergyar | Drug solutions of increased stability and without tissue-damaging effect and process for preparing same |
US5654003A (en) * | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
US20080234380A1 (en) * | 1992-06-30 | 2008-09-25 | Shapiro Howard K | Compositions and method for treatment of chronic inflammatory diseases |
US5304561A (en) * | 1992-07-24 | 1994-04-19 | Faezeh Sarfarazi | New concept in glaucoma treatment |
US5380934A (en) * | 1992-10-29 | 1995-01-10 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing alanylgutamine |
US5886030A (en) * | 1994-05-06 | 1999-03-23 | Alcon Laboratories, Inc. | Use of vitamin E tocopheryl derivatives in ophthalmic compositions |
US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
US6221377B1 (en) * | 1995-11-13 | 2001-04-24 | Pitmy International N.V. | Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs |
US6187800B1 (en) * | 1996-06-20 | 2001-02-13 | Novartis Animal Health U.S., Inc. | Method for the prevention and treatment of mastitis |
US20020068088A1 (en) * | 1996-08-15 | 2002-06-06 | Peter Gruber | Easy to swallow oral medicament composition |
US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6630056B1 (en) * | 1997-07-10 | 2003-10-07 | Thibierge & Comar | Color tracing paper |
US6605295B1 (en) * | 1997-07-11 | 2003-08-12 | Bausch & Lomb Incorporated | Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin |
US6284269B1 (en) * | 1997-08-27 | 2001-09-04 | Hexal Ag | Pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
US6599529B1 (en) * | 1997-09-11 | 2003-07-29 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs) |
US20020099049A1 (en) * | 1997-09-17 | 2002-07-25 | Burch Ronald M. | Analgesic combination of oxycodone and meloxicam |
US6046191A (en) * | 1997-10-10 | 2000-04-04 | Astra Pharmaceuticals Ltd. | Combination |
US5962012A (en) * | 1997-11-28 | 1999-10-05 | Caleb Pharmaceuticals, Inc. | Cholinergic antagonist patch |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
US6869948B1 (en) * | 1998-03-27 | 2005-03-22 | Boehringer Ingelheim Pharma Kg | Meloxicam for oral administration |
US6184220B1 (en) * | 1998-03-27 | 2001-02-06 | Boehringer Ingelheim Pharma Kg | Oral suspension of pharmaceutical substance |
US6682747B1 (en) * | 1998-03-27 | 2004-01-27 | Boehringer Ingelheim Pharma Kg | Process for preparing an oral suspension of a pharmaceutical substance |
US6495603B1 (en) * | 1998-05-15 | 2002-12-17 | Wakamoto Pharmaceutical Co., Ltd. | Anti-inflammatory eye drop |
US6319519B2 (en) * | 1998-07-07 | 2001-11-20 | Norton Healthcare Ltd. | Anti-inflammatory pharmaceutical formulations |
US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
US6986346B2 (en) * | 1998-10-17 | 2006-01-17 | Boehringer Ingelheim Pharma Kg | Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
US6180136B1 (en) * | 1998-11-10 | 2001-01-30 | Idexx Laboratories, Inc. | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
US6156349A (en) * | 1998-12-14 | 2000-12-05 | Steinbach, Pylant And Herman, L.L.C. | Method of treating HIV infection with suppository containing mammalian liver extract |
US6183779B1 (en) * | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
US6166012A (en) * | 1999-07-30 | 2000-12-26 | Allergan Sales, Inc. | Antibiotic compositions and method for using same |
US6669957B1 (en) * | 1999-09-15 | 2003-12-30 | Cll Pharma | Galenic formulations fast disintegrating in the mouth and method for preparing same |
US20030055051A1 (en) * | 1999-11-24 | 2003-03-20 | Wakamoto Pharmaceutical Co., Ltd. | Ophthalmic aqueous pharmaceutical preparation |
US7105512B2 (en) * | 1999-11-24 | 2006-09-12 | Wakamoto Pharmaceutical Co., Ltd. | Ophthalmic aqueous pharmaceutical preparation |
US20020106345A1 (en) * | 1999-12-07 | 2002-08-08 | Uhrich Kathryn E. | Therapeutic compositions and methods |
US6550955B2 (en) * | 2000-05-03 | 2003-04-22 | D'silva Joe | Process for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules using a mixing cup with an abrasive interior surface |
US20020016342A1 (en) * | 2000-05-15 | 2002-02-07 | Edward Scolnick | Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
US20030050305A1 (en) * | 2000-05-22 | 2003-03-13 | Tejada Inigo Saenz De | Thromboxane inhibitors, compositions and methods of use |
US20020035107A1 (en) * | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
US20060079516A1 (en) * | 2000-06-20 | 2006-04-13 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions |
US20040024041A1 (en) * | 2000-07-01 | 2004-02-05 | Torsten Selzer | Dermal therapeutic system containing non-steroidal antiphlogistics with selective cox-2 inhibition |
US20020006440A1 (en) * | 2000-07-05 | 2002-01-17 | Cherukuri Subraman Rao | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
US20020077328A1 (en) * | 2000-07-13 | 2002-06-20 | Fred Hassan | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain |
US20040204413A1 (en) * | 2001-01-26 | 2004-10-14 | Joaquina Faour | Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant |
US20030199482A1 (en) * | 2001-03-28 | 2003-10-23 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
US20020187187A1 (en) * | 2001-04-21 | 2002-12-12 | Toshimitsu Ohki | Fast disintegrating meloxicam tablet |
US20040234596A1 (en) * | 2001-04-21 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Fast disintegrating meloxicam tablet |
US20050244491A1 (en) * | 2001-04-21 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Fast disintegrating meloxicam tablet |
US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
US20030220306A1 (en) * | 2001-09-28 | 2003-11-27 | Daniel Simmons | Novel cyclooxygenase variants and methods of use |
US20030109701A1 (en) * | 2001-12-11 | 2003-06-12 | Laura Coppi | Crystalline forms of meloxicam and processes for their preparation and interconversion |
US20080132493A1 (en) * | 2001-12-12 | 2008-06-05 | Martin Andreas Folger | Highly concentrated stable meloxicam solutions for needleless injection |
US20030119825A1 (en) * | 2001-12-12 | 2003-06-26 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions for needleless injection |
US20040001883A1 (en) * | 2002-03-30 | 2004-01-01 | Boehringer Ingelheim International Gmbh | Meloxicam suppositories |
US20040024042A1 (en) * | 2002-04-02 | 2004-02-05 | Vanderbilt University | COX2 inhibition in the prevention and treatment of autosomal dominant polycystic kidney disease |
US20040043992A1 (en) * | 2002-05-22 | 2004-03-04 | Boehringer Ingelheim International Gmbh | Meloxicam for alleviating organ injury during organ operation or transplantation |
US20040037869A1 (en) * | 2002-08-16 | 2004-02-26 | Douglas Cleverly | Non-animal product containing veterinary formulations |
US20050187212A1 (en) * | 2002-09-17 | 2005-08-25 | Nippon Boehringer Ingelheim Co., Ltd. | Pharmaceutical composition for topical delivery of meloxicam |
US20040171611A1 (en) * | 2002-09-30 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline acetic acid solvate of meloxicam |
US20040180092A1 (en) * | 2002-10-25 | 2004-09-16 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
US20040110747A1 (en) * | 2002-12-06 | 2004-06-10 | Boehringer Ingelheim International Gmbh | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
US20050197332A1 (en) * | 2002-12-10 | 2005-09-08 | Boehringer Ingelheim International | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
US20070099907A1 (en) * | 2002-12-10 | 2007-05-03 | Raul Altman | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
US20060160793A1 (en) * | 2002-12-10 | 2006-07-20 | Boehringer Ingelheim International Gmbh | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
US20040229038A1 (en) * | 2003-03-03 | 2004-11-18 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
US20040204472A1 (en) * | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
US20040214753A1 (en) * | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
US20040198826A1 (en) * | 2003-04-07 | 2004-10-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination for treating benign prostatic hyperplasia or for treating abacterial prostatitis |
US20120077764A1 (en) * | 2003-05-29 | 2012-03-29 | Freehauf Keith A | Compositions and method for treating infection in cattle and swine |
US20050038018A1 (en) * | 2003-07-09 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Meloxicam compositions |
US20050147664A1 (en) * | 2003-11-13 | 2005-07-07 | Elan Pharma International Ltd. | Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery |
US20050187213A1 (en) * | 2004-02-23 | 2005-08-25 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam for the treatment of respiratory diseases in pigs |
US20050245510A1 (en) * | 2004-04-29 | 2005-11-03 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam formulations in veterinary medicine |
US20050277634A1 (en) * | 2004-05-19 | 2005-12-15 | Boehringer Ingelheim Vetmedica Gmbh | Liquid composition for veterinary medicine and process for the preparation and use thereof |
US20050288280A1 (en) * | 2004-06-23 | 2005-12-29 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam in veterinary medicine |
US20060217431A1 (en) * | 2005-03-23 | 2006-09-28 | Boehringer Ingelheim International Gmbh | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor |
US20070077296A1 (en) * | 2005-09-30 | 2007-04-05 | Folger Martin A | Pharmaceutical Preparation containing Meloxicam |
US7969206B2 (en) * | 2007-05-21 | 2011-06-28 | Denso Corporation | Semiconductor element drive circuit |
US20110275618A1 (en) * | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim Vetmedica Gmbh | Novel low concentration meloxicam tablets |
Non-Patent Citations (1)
Title |
---|
Zaghawa et al. (Clinical and Etiological study on respiratory affections of sheep By Zaghawa A., Hassan H., and El-Sify A. Faculty of veterinary medicine-Sadat city -Menoufia University Animal medicine and infectiuos diseases department Abstract). * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060079516A1 (en) * | 2000-06-20 | 2006-04-13 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions |
US9993557B2 (en) | 2000-06-20 | 2018-06-12 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions |
US9956288B2 (en) | 2000-06-20 | 2018-05-01 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions |
US20080132493A1 (en) * | 2001-12-12 | 2008-06-05 | Martin Andreas Folger | Highly concentrated stable meloxicam solutions for needleless injection |
US10098891B2 (en) | 2001-12-12 | 2018-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions for needleless injection |
US8920820B2 (en) | 2001-12-12 | 2014-12-30 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions for needleless injection |
US20040180092A1 (en) * | 2002-10-25 | 2004-09-16 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
US9066955B2 (en) | 2002-10-25 | 2015-06-30 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
US11083731B2 (en) | 2004-02-23 | 2021-08-10 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam for the treatment of respiratory diseases in pigs |
US10548901B2 (en) | 2004-02-23 | 2020-02-04 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam for the treatment of respiratory diseases in pigs |
US20050245510A1 (en) * | 2004-04-29 | 2005-11-03 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam formulations in veterinary medicine |
US20050288280A1 (en) * | 2004-06-23 | 2005-12-29 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam in veterinary medicine |
US20070077296A1 (en) * | 2005-09-30 | 2007-04-05 | Folger Martin A | Pharmaceutical Preparation containing Meloxicam |
US9186296B2 (en) | 2009-10-12 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
US9101529B2 (en) | 2009-10-12 | 2015-08-11 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
US20110083985A1 (en) * | 2009-10-12 | 2011-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
US9149480B2 (en) | 2010-03-03 | 2015-10-06 | Boehringer Ingeleheim Vetmedica GmbH | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
US9943486B2 (en) | 2010-05-05 | 2018-04-17 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
Also Published As
Publication number | Publication date |
---|---|
SG150531A1 (en) | 2009-03-30 |
RU2360680C2 (en) | 2009-07-10 |
CN1921865B (en) | 2010-06-16 |
EP1720554A1 (en) | 2006-11-15 |
JP2007523205A (en) | 2007-08-16 |
JP5009147B2 (en) | 2012-08-22 |
BRPI0507966A (en) | 2007-07-17 |
KR20070033960A (en) | 2007-03-27 |
DK1720554T3 (en) | 2012-10-15 |
ES2394038T3 (en) | 2013-01-16 |
US11083731B2 (en) | 2021-08-10 |
TW200533362A (en) | 2005-10-16 |
EP1720554B1 (en) | 2012-07-18 |
CA2554040C (en) | 2014-08-05 |
CA2554040A1 (en) | 2005-09-01 |
WO2005079806A1 (en) | 2005-09-01 |
US20180185380A1 (en) | 2018-07-05 |
US20050187213A1 (en) | 2005-08-25 |
UA92584C2 (en) | 2010-11-25 |
KR101233359B1 (en) | 2013-02-13 |
RU2006133829A (en) | 2008-03-27 |
AU2005215122A1 (en) | 2005-09-01 |
US20140179639A1 (en) | 2014-06-26 |
US20200121692A1 (en) | 2020-04-23 |
EP1568369A1 (en) | 2005-08-31 |
AU2005215122B2 (en) | 2011-08-11 |
MXPA06009575A (en) | 2007-03-15 |
CN1921865A (en) | 2007-02-28 |
US10548901B2 (en) | 2020-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11083731B2 (en) | Meloxicam for the treatment of respiratory diseases in pigs | |
Wilson | Rational selection of antimicrobials for use in horses | |
EP1462101B1 (en) | Drinkable preparation comprising ketoprofen and use thereof in the simultaneous treatment of a group of animals of respiratory diseases | |
EP2293777B1 (en) | Pharmaceutical transdermal compositions and method for treating inflammation in cattle | |
Constable et al. | Guidelines for antimicrobial use in cattle | |
US20110144048A1 (en) | Novel Uses of Neuraminidase Inhibitors in Infectious Diseasess | |
US20210196685A1 (en) | Composition for eradicating helicobacter pylori | |
ES2230802T3 (en) | TREATMENT OF VIRAL INFECTION IN CERCOS. | |
JP5322649B2 (en) | Cefquinome composition and method of use thereof | |
SK284791B6 (en) | Use of 8a-azalides in the treatment or prevention of bacterial respiratory and enteric infections in livestock animals | |
US20180235941A1 (en) | Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and methods for using same | |
KR20040106673A (en) | Composition for scours treatment of domestic animals and treatment using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANG, INGO;PAPATSAS, IOANNIS;SIGNING DATES FROM 20050330 TO 20050404;REEL/FRAME:051177/0810 |